dc.contributor.author | Zusinaite, Eva | |
dc.contributor.author | Ianevski, Alexandr | |
dc.contributor.author | Niukkanen, Diana | |
dc.contributor.author | Poranen, Minna M. | |
dc.contributor.author | Bjørås, Magnar | |
dc.contributor.author | Afset, Jan Egil | |
dc.contributor.author | Tenson, Tanel | |
dc.contributor.author | Velagapudi, Vidya | |
dc.contributor.author | Merits, Andres | |
dc.contributor.author | Kainov, Denis | |
dc.date.accessioned | 2019-03-14T12:50:19Z | |
dc.date.available | 2019-03-14T12:50:19Z | |
dc.date.created | 2018-09-16T20:05:57Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Viruses. 2018, 10:423 (8), 1-13. | nb_NO |
dc.identifier.issn | 1999-4915 | |
dc.identifier.uri | http://hdl.handle.net/11250/2590051 | |
dc.description.abstract | There are dozens of approved, investigational and experimental antiviral agents. Many
of these agents cause serious side effects, which can only be revealed after drug administration.
Identification of the side effects prior to drug administration is challenging. Here we describe
an ex vivo approach for studying immuno- and neuro-modulatory properties of antiviral agents,
which may be associated with potential side effects of these therapeutics. The current approach
combines drug toxicity/efficacy tests and transcriptomics, which is followed by mRNA, cytokine
and metabolite profiling. We demonstrated the utility of this approach with several examples of
antiviral agents. We also showed that the approach can utilize different immune stimuli and cell
types. It can also include other omics techniques, such as genomics and epigenomics, to allow
identification of individual markers associated with adverse reactions to antivirals with immuno-
and neuro-modulatory properties. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | MDPI | nb_NO |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | A systems approach to study immuno- and neuro-modulatory properties of antiviral agents | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 1-13 | nb_NO |
dc.source.volume | 10:423 | nb_NO |
dc.source.journal | Viruses | nb_NO |
dc.source.issue | 8 | nb_NO |
dc.identifier.doi | 10.3390/v10080423 | |
dc.identifier.cristin | 1609880 | |
dc.description.localcode | © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | nb_NO |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |